title: [New substances in the therapy of head and neck cancer].
abstract: During the last 3 years the FDA approved numerous innovative drugs for cancer therapy. Drugs relevant to the otolaryngologist are presented and discussed. These new therapeutic tools may play a future part also in the therapy of head and neck cancer.
authors.affiliation: Universitäts-HNO-Klinik Ulm. fellixb@yahoo.com
authors.forename: F
authors.initials: F
authors.lastname: Bogeschdorfer
authors.forename: S
authors.initials: S
authors.lastname: Gronau
authors.forename: H
authors.initials: H
authors.lastname: Riechelmann
mesh_terms: D000284:Administration, Oral; D000634:Aminoquinolines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000068258:Bevacizumab; D002280:Basal Cell Carcinoma / Q000188:drug therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000401:mortality; D000068818:Cetuximab; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy; D018849:Controlled Clinical Trials as Topic; D004311:Double-Blind Method; D000069347:Erlotinib Hydrochloride; D051523:Fibroblast Growth Factor 7 / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000077156:Gefitinib; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D000077271:Imiquimod; D007262:Infusions, Intravenous; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality; D008207:Lymphatic Metastasis; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000532:radiotherapy; D009824:Ointments; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D016499:Radioimmunotherapy; D016032:Randomized Controlled Trials as Topic; D012878:Skin Neoplasms / Q000188:drug therapy; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000634:Aminoquinolines; D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D007457:Iodine Radioisotopes; D009824:Ointments; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D051523:Fibroblast Growth Factor 7; D000068258:Bevacizumab; D000069347:Erlotinib Hydrochloride; C119496:tositumomab I-131; D000077271:Imiquimod; D000068818:Cetuximab; D000077156:Gefitinib